-
November 19, 2025Umecrine Cognition publishes review highlighting the therapeutic potential of golexanolone in treating neuroinflammatory disordersSTOCKHOLM – November 19, 2025. Umecrine Cognition today announced that a review article on golexanolone, a first-in-class drug candidate targeting...
-
November 17, 2025Umecrine Cognition reports early golexanolone treatment yields sustained benefit in a preclinical model of Parkinson’s diseaseSTOCKHOLM – November 17, 2025. Umecrine Cognition AB today announced publication in Neuropharmacology of findings which show that early treatment...
-
October 9, 2025Notice to attend the Extraordinary General Meeting in Umecrine Cognition AB, at 2:30 p.m.STOCKHOLM – October 9, 2025 The shareholders in Umecrine Cognition AB, reg. no. 556698-3655, are hereby given notice to attend an extraordinary...
Latest Annual Report
Subscribe
Our drug projects
GABAA receptor modulating steroid antagonists: our scientific focus
Our lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.